Abstract：Objective To investigate the clinical significance of T helper type 9 (Th9) cells and interleukin-9 (IL- 9) in children suffering from Mycoplasma pneumoniae (MP) infection. Methods A total of 86 children who were diagnosed with MP infection between January 2013 and June 2014 were classified into upper respiratory infection (URI) group (n=29), mild MP pneumonia (MPP) group (n=32) and severe MPP group (n=25). Twenty-eight healthy children were used as the control group. Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation, and the percentage of Th9 cells in peripheral blood was measured by flow cytometry. Serum IL-9 level was determined using ELISA. Results The URI, mild MPP, and severe MPP groups had significantly higher percentages of Th9 cells and IL-9 levels than the control group (P<0.05); the mild MPP and severe MPP groups had significantly higher percentages of Th9 cells and IL-9 levels than the URI group (P<0.05), and the two indices were significantly higher in the severe MPP group than in the mild MPP group (P<0.01). Conclusions Children with MP infection have an elevated percentage of Th9 cells and IL-9 expression, both of which are positively correlated with the severity of the disease. It can be predicted that Th9 cells and IL-9 can be used as evaluation indicators for the progression and outcome of children with MP infection.
WANG Jian-Yong,ZHENG Jing,XING Hai-Yan et al. Determination of Th9 cells and IL-9 in children with Mycoplasma pneumoniae infection[J]. CJCP, 2015, 17(4): 308-311.
Cao B, Ren LL, Zhao F, et al. Viral and Mycoplasma pneumonia community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(11): 1443-1448.
[2]
Veldhoen M, Uyttenhove C, Van Snick J, et al. Transforming growth factor-beta ‘reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset[J]. Nat Immunol, 2008, 9(12): 1341-1346.
Bae JW, Kim HJ, Chang GY, et al. Combined striatum, brain stem, and optic nerve involvement due to Mycoplasma pneumoniae in an ambulatory child[J]. Case Rep Neurol, 2011, 3(2): 109-112.
[6]
Yang J, Hooper WC, Phillips DJ, et al. Cytokines in Mycoplasma pneumoniae infections[J]. Cytokine Growth Factor Rev, 2004, 15(2-3): 157-168.
Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-betainduced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells[J]. Nat Immunol, 2008, 9(12): 1347-1355.
[10]
Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function[J]. Protein Cell, 2011, 2(8): 604- 611.
[11]
Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice[J]. Cytokine, 2004, 26(3): 122-130.
[12]
Xing J, Wu Y, Ni B. Th9: a new player in asthma pathogenesis?[J]. J Asthma, 2011, 48(2): 115-125.
[13]
Ciprandi G, De Amici M, Marseglia GL. Serum IL-9 levels and sublingual immunotherapy: preliminary report[J]. J Biol Regul Homeost Agents, 2011, 25(2): 295-297.
[14]
Devos S, Cormont F, Vrtala S, et al. Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin- 13[J]. Clin Exp Allergy, 2006, 36(2): 174-182.
Yanaba K, Yoshizaki A, Asano Y, et al. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis[J]. J Rheumatol, 2011, 38(10): 2193-2197.
[17]
Parker JM, Oh CK, LaForce C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma[J]. BMC Pulm Med, 2011, 11: 14.
